Evaluation of a novel phytase derived from Citrobacter braakii and expressed in Aspergillis oryzae on growth performance and bone mineralization indicators in nursery pigs.

A total of 297 pigs (DNA 241 × 600; initially 8.64 ± 0.181 kg) were used in a 21-d trial to determine the efficacy of a novel phytase derived from Citrobacter braakii and expressed in Aspergillis oryzae (HiPhorius; DSM Nutritional Products, Animal Nutrition & Health, Parsippany, NJ) on pig growth and bone mineralization indicators.

Impacts of a post-transport/pre-processing rest period on the growth performance, anthelmintic efficacy, and serum metabolite changes in cattle entering a feed yard.

A total of 80 crossbred, high-risk heifers (initially 250 ± 4.2 kg BW), were transported from an Oklahoma City, Oklahoma sale barn to the Kansas State University Beef Cattle Research Center. Cattle were unloaded and randomly placed into one of four receiving pens and provided ad libitum hay and water.

Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice.

Bendamustine has demonstrated clinical activity and a favorable safety profile as monotherapy or in combination with rituximab in lymphoid malignancies. As interventional trials do not always reflect clinical reality, we were interested in the treatment modalities and the outcome of bendamustine-based first-line therapy in patients with advanced indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL) in routine practice. Between April 2010 and October 2011, 324 patients were enrolled in a prospective non-interventional multicenter study.

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.

Background: Superiority of irinotecan/cisplatin over etoposide/cisplatin was suggested in small-cell lung cancer (SCLC). This trial investigated irinotecan/carboplatin (IP) versus etoposide/carboplatin (EP).

Patients And Methods: The interim analysis at the phase II/phase III transition point of the multicenter trial is reported.